http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
B 형 간염바이러스 양성인 간경변환자에서 간 이식시 Immunoprophylaxis 후 1 년이상 HBV DNA 및 HBsAg 소실을 보인 1 예
윤승규(Seung Kew Yoon),정재열(Jae Youl Jeong),신제현(Je Hyeon Shin),장상아(Sang Ah Jang),이창돈(Chang Don Lee),박두호(Doo Ho Park),김부성(Boo Sung Kim),오승택(Seung Taek Oh),김동구(Dong Goo Kim),고용복(Yong Bok Koh),김인철(In Chul Ki 대한내과학회 1995 대한내과학회지 Vol.49 No.1
Orthotopic liver transplantation(OLT) in hepatitis B virus(HBV) associated liver diseases remains controversial because of the high recurrence of HBV reinfection. To prevent this reinfection a passive immunoprophylaxis with Hepatitis B immunoglobulin(HBIG), HBV vaccine and interferon have been attempt- ed. In our report, serum HBsAg and HBV DNA of the patient were positive before OLT. We administered intravenously 10,000 IU HBIG during the anhepatic phase, followed by 1,000 IU daily for the first postoperative week. Circulating HBsAg by radioimmunoassay(RIA) and HBV DNA or HCV RNA by polymerase chain reaction(PCR) were not detected to postopertive 53th weeks. In conclusion, passive immunoprophylaxis was able to reduce risk of recurrent HBV infection in HBV DNA positive patient before OLT. Therefore, patients with end stage liver diseases associated HBV infection cannot be considered a relative contraindication to DLT.
수혈후 비 A 형 비 B 형 간염 환자혈청에서 분리한 C 형 간염 바이러스 유전자의 부분 염기서열분석
윤승규(Seung Kew Yoon),박영민(Young Min Park),정규원(Kyu Won Chung),김부성(Boo Sung Kim),김원용(Won Yong Kim),김철중(Chul Joong Kim) 대한내과학회 1994 대한내과학회지 Vol.46 No.1
Objectives: Since hepatitis C virus (HCV) has been discovered, many strains of HCV have been isolated partially or completely and charaterized under molecular biologic level. Recently, several kinds of HCV typing method have been developed and the differences in the geographical distribution of each type were reported and the possibility that the viral pathogencecity and clinical significance according to HCV type may be different has been also suggested. Methods: To investigate the molecular biologic property of HCV isolated from two posttransfusion non A, non-B hepatitis (PT-NANRH) patients in Korea, we performed a molecular typing of HCV genome using reverse transcription-polymerase chain reaction (RT- PCR) with type specific primer sets deduced from NS5 region and a cloning-sequencing using the PCR products. Results: 1) In HCV typing by RT-nested PCR, one case showed a HCV-J type while the other case showed a HCV-J/K1 type. 2) At the nucletide level, the homologies between isolated 2 HCV genomes and HCV-J, -K1 type ranged from 93.0~93.5% to 91.5~93.5% respectively. 3) Deduced amino acid sequence homologies of 2cases ranged from 95.5~97.0% with HCV-J type and 92.4~95.5%. with HCV-K1 type. Conclusion: These results showed that HCU genome isolated from Korean patients were highty identical to HCV-J or HCV-K1 which were recognized as a major type in Japan, while it suggests that HCV type II corresponding to HCV-J or-K1 type may be the major type in Korea. To understand the pathogenesis of HCV and develope a diagnostic tool or vaccine for HCV compatible to Korean strains, more genetic information on the HCV genome isolated from Korean patients will be required.
윤승규 ( Seung Kew Yoon ),( Dur Han Kwon ),( Hyun Jung Kim ),( Eun Joo Chang ),( Hyok Yun Kwon ),( Jong Young Choi ),( Si Hyun Bae ),( Kyu Won Chung ),( Hee Sik Sun ),( Doo Ho Park ) 대한소화기학회 2002 대한소화기학회 춘계학술대회 Vol.2002 No.-
<Objective> The purpose of this study was to evaluate a antiviral effect and safety of aqueous extract from A. Eupatoria on hepatitis B virus(HBV) infection in vitro and vivo. <Methods> To determine the antiviral activity of A Eupatoria in vitro, we used
윤승규 ( Seung Kew Yoon ),( Se Hwan Yang ),( Young Chul Sung ),( Jong Young Choi ),( Byung Hoon Byun ),( Si Hyun Bae ),( Kyu Won Chung ),( Hee Sik Sun ),( Doo Ho Park ) 대한소화기학회 2002 대한소화기학회 춘계학술대회 Vol.2002 No.-
<Objective> In the absence of an efficient cell culture system to study hepatitis C virus(HCV), transgenic mice in which HCV core is expressed in the liver under the control of hepatitis B virus regulatory element, have been produced. The aim of this stud
윤승규 ( Seung Kew Yoon ) 대한간학회 2012 Postgraduate Courses (PG) Vol.2012 No.-
Minimal encephalopathy (MHE) is the leading cause of cognitive dysfunction in patients with liver cirrhosis who are characterized by abnormal responses to psychometric and/or neurophysiological tests without clinically abnormal feature. Patients with MHE have poor-health-related quality of life (HRQOL) and thus have difficulty to have job, resulting in poor socio-economic life. Moreover, the patients with MHE meet frequent life-threatening risk due to cognitive dysfunction throughout their life. In particular, recent reports have demonstrated that patients with MHE are unfit to drive in 52% to 100% of cases. Although there is still debate over whether active treatment for patients with MHE is needed or not in terms of cost-effectiveness, recent studies have suggested that active treatment for MHE could improve HRQOL, enhance driving ability, and eventually may prevent the development of overt hepatic encephalopathy.
윤승규 ( Seung Kew Yoon ) 대한간학회 2017 간학회 싱글토픽 심포지움 Vol.2017 No.1
Chronic hepatitis B virus (HBV) infection remains a major public health problem. Despite recent advances in antiviral agents including oral nucleos(t)ide, complete eradication of the virus has been difficult to achieve. Therefore, there is urgent need for development of new antiviral strategy to achieve the induction of stronger and broader immune response against HBV. Although therapeutic vaccination for the treatment of chronic hepatitis B has shown limited clinical efficacy until now, it is still considered to be a promising growth area. Here, the author review and discuss therapeutic vaccination as a new modality for the treatment of chronic HBV infection.
만성 B형 간염에 대한 인터페론 알파 - 2a의 치료효과
윤승규(Seung Kew Yoon),조현미(Hyun Mi Cho),박영민(Young Min Park),심규식(Kyu Sik Shim),이창돈(Chang Don Lee),백남종(Nam Jong Baeg),차상복(Sang Bok Cha),박두호(Doo Ho Park),김부성(Boo Sung Kim) 대한소화기학회 1994 대한소화기학회지 Vol.26 No.1
N/A To evaluate the effect of recombinant interferon alfa-2a in chronic hepatitis B, we randomly assigned 47 patients with chronic hepatitis B to four groups: HBeAg(+)/anti-Hbe( ) group I (n=9), treated with 3 MU of interferon alfa-2a every day for 6 months; HBeAg(+)/anti-Hbe ( ) group II(n=10), treated with 3MU of IFN alfa-2a every day for 1 month followed by every other day for 5 months; HBeAg( )/anti-Hbe(+) group lII(n=8), treated with IFN alfa-2a per every other day for 6 months; untreated(control) group IV(n=20). At the end of the treatment (6th month), the normalization of serum ALT was 6/9(66.7%) in group I, 7/10(70.0%) in group LI, 2/8(25.0%) in group III and 7/20(35.0%) in untreated group, but there was no significant difference between the treated group with IFN and untreated group. The seroconversion of HBeAg was 2/9(22.2%) in group I, 3/10(30.0%) in group II and 2/ 20(10.0%) in untreated group. Hepatitis B virus DNA was negative in 25.0% in group I, 20.0% in group II, 28.6% in group III and 5.0% in untreated group, however significant difference was not noted between treated groups and untreated group. Seroconversion of HBsAg was ob- served in the one patient who belonged to group II. Paired t-test in the comparison of biochemical tests before and after treatment of IFN in group I, -II and -tII revealed that serum ALT level significantly decreased in group I (p<0. 05), serum albumin level was significantly increased in group I, -II, and -lII(p<0,05, p<0.01), serum alkaline phosphatase and significantly decreased in group I (p<0.05). All patients with IFN alfa-2a complained of transient flu-like symptom, but not serious and there was no other side effect to withdrawal treatment. These results suggest that IFN alfa-2a in chronic hepatitis B does not have a powerful anti- viral effect but seems to be relatively effective and tolerable.(Korean J Gastroenterol 1994;26: 109 118)